The healthy human appendix contains Parkinson’s disease-related alpha-synuclein aggregates, and removing the organ early in a person’s life reduces the risk of developing the disease, a study has found. The study, “The vermiform appendix impacts the risk of developing Parkinson’s disease,” was published in Science…

Reduced alpha-synuclein levels in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — are associated with more severe non-motor symptoms in Parkinson’s patients, according to a study. The study, “CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD…

A new transgenic Parkinson’s disease mouse model is able to recapitulate the motor symptoms and biological causes of disease, including alpha-synuclein protein aggregation, a study reports. Similar to Parkinson’s patients, this model also responds to levodopa, one of the main compounds used to treat symptoms of the disease. The study, “Abrogating Native…

A better understanding of how Parkinson’s disease affects the laryngopharyngeal muscles of the esophagus could help identify those patients at risk for obstructive sleep apnea, according to a new study. The research, “Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinson’s disease,” was published in the journal Sleep and…

Parkinson’s researchers need to focus on human cells and tissues, implement modern computer modeling approaches, and shift away from animal models, according to a recent study. Earlier transition from preclinical studies to clinical trials also could be beneficial, the study authors suggest. The study, “Parkinson’s disease…

Eradicating Helicobacter pylori infections could improve motor function, ease gut symptoms and increase levodopa’s effectiveness in Parkinson’s patients, according to a review study. The research, “Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson’s Disease,” was published in the Journal of Parkinson’s Disease.

A gene editing approach targeting a specific part of the SNCA gene was able to lower alpha-synuclein levels and protect from Parkinson’s characteristic cellular changes, according to preclinical results. The study, “Downregulation of SNCA expression by targeted editing of DNA-methylation: A potential strategy for precision therapy in…

Using a new screening strategy, researchers have identified compounds that block the clumping of alpha-synuclein protein, a key event in Parkinson’s. The study, “Potent α-Synuclein Aggregation Inhibitors, Identified by High-Throughput Screening, Mainly Target the Monomeric State,” appeared in the journal Cell Chemical Biology. Aggregated alpha-synuclein is…

Alterations in certain types of fat in a brain area called the substantia nigra may result in elevated levels of the GPNMB protein and drive neurodegeneration in Parkinson’s disease patients, according to Harvard researchers. The study, titled “The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients…

The Parkinson’s Foundation announced that it investing $6.2 million across 53 research grants, part of its commitment to advancing promising work into the disease. The grants will support Parkinson’s clinical trials and research centers. They also include career development and fellowships for scientists working in multiple aspects of related research. “Our goal at…